Please login to the form below

Not currently logged in
Email:
Password:

China recalls GSK antibiotic

Chinese authorities have recalled GlaxoSmithKline's antibiotic Augmentin after traces of a compound used to make plastics more flexible were found in the treatment's syrup form

Chinese authorities have recalled GlaxoSmithKline's (GSK) antibiotic Augmentin (amoxicillin and clavulanate potassium) after traces of a compound used to make plastics more flexible were found in the treatment's syrup form.

Test results have shown the plasticiser diisodecyl phthalate (DIDP) is present in the antibiotic, according to China's State Food and Drug Administration. DIDP is banned in the production of medicines.

GSK has been ordered to immediately suspend sales of the product, which is regularly used to treat infections in children.

As reported in the UK's Daily Telegraph, a GSK spokesperson said: "GSK is currently in discussion with a number of regulatory agencies in the Asia Pacific region, some of whom have also conducted tests."

"The amount of phthalates identified as present in Augmentin syrup samples tested is very low; some tests have found none and the highest level reported by the authorities is 88 parts per million. Even this highest result is significantly lower than the levels that the US and European authorities deem as presenting no risk to humans."

Taiwan and Hong Kong had previously demanded GSK recall Augmentin after it was found to contain DIPD.

21st June 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics